Work

Phase I/II study of rilotumumab (R) and erlotinib (E) in previously treated patients (pts) with metastatic NSCLC.

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.8092

Authors: Ahmad A. Tarhini, Imran Rafique, Phu Tran, William E. Gooding, Liza Cosca Villaruz, Timothy Francis Burns, David Friedland, Grace R. Tarabay, Andrew D. Laman, Dhaval R. Mehta, Matthew Gerard Sulecki, Daniel P. Petro, Mark S. Georgiadis, Kevin M. Kane, Sajid M. Peracha, Kiran K. Rajasenan, Alexis Megaludis, Lijun Dai, Mark A. Socinski

Institutions: UPMC Hillman Cancer Center, University of Pittsburgh, University of Pittsburgh Medical Center, UPMC Health System, UPMC McKeesport

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2603396766

Cites:

Cited by:

Related to: 10